Otros idiomas Nova Mentis Life Science Corp.

Acciones

NOVA

CA66980V1067

Mercado cerrado - Canadian Securities Exchange Otros sitios de cotización 21:38:53 25/04/2024			Varia. Cinco días.	Varia. 1 de enero.
0,015 ^CAD	0,00 %		+50,00 %	-25,00 %

08/04	Nova Mentis Life Science Corp. presenta los resultados del ejercicio cerrado el 31 de diciembre de 2023	CI
26/02	Nova Mentis Life Science Corp. anuncia el nombramiento de Steve Loutskou para el Consejo de Administración	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Nova Mentis Life Science Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	08/04
Nova Mentis Life Science Corp. Announces the Appointment of Steve Loutskou to the Board of Directors	26/02
Nova Mentis Announces Change of Directors	26/02
Nova Mentis Life Science Corp. Announces Management Changes	04/01
Nova Mentis Life Science Corp. Announces Resignation of Dr. Stephen Glazer as Chief Scientific Officer and Director	11/12
Nova Mentis Life Science Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	29/11
Nova Mentis Life Science Corp.: Nova Mentis begrüßt Entscheidung der Regierung zur Einrichtung einer Beratergruppe für seltene Krankheiten	03/11
Nova Mentis Applauds Government Decision to Create Rare Disease Advisory Group	03/11
Nova Mentis Life Science Corp. - Participant Screening Underway in Canada's First Psilocybin Clinical Trial for Fragile X Syndrome	31/08/23
Nova Mentis Life Science Corp. Announces Participant Screening Underway in Canada's First Psilocybin Clinical Trial for Fragile X Syndrome	30/08/23
Nova Mentis Life Science Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	29/08/23
Nova Mentis Life Science Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	31/05/23
Nova Mentis Life Science Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	25/04/23
Nova Mentis Life Science Corp. Auditor Raises 'Going Concern' Doubt	25/04/23
Nova Mentis Begins Recruitment in First-of-its-Kind Health Canada Psilocybin Trial	19/04/23
KGK Science Inc. Begins Recruitment in First-of-its-Kind Health Canada Approved Psilocybin Trial	18/04/23
KGK Sciences Inc. Begins Recruiting Participants, on Behalf of Client Nova Mentis Life Science Corp. in First-Ever Clinical Trial Investigating Effects of Psilocybin on Adults Diagnosed with Fragile X Syndrome	18/04/23
Nova Mentis Receives Institutional Review Board Approval to Commence Psilocybin Clinical Trial	12/04/23
Nova Mentis Life Science Corp. Receives Institutional Review Board Approval to Commence Psilocybin Clinical Trial	11/04/23
Nova Mentis Provides Corporate Update and 2023 Outlook	06/04/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Nova Mentis Life Science Corp.

Acciones

NOVA

CA66980V1067

Otros idiomas

Filtros